This site is intended for Healthcare professionals only.
×

Abbvie to record $4 billion impairment charges on Stemcentrx assets


Abbvie to record $4 billion impairment charges on Stemcentrx assets

The drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as it aimed to enter the broad and lucrative arena of solid tumours and lessen dependence on its blockbuster arthritis treatment Humira.

United States: Abbvie Inc on Friday said it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy.

The drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as it aimed to enter the broad and lucrative arena of solid tumours and lessen dependence on its blockbuster arthritis treatment Humira.

Read Also: AbbVie stops enrollment for a late-stage trial of Rova-T

In December, Abbvie halted enrollment for a late-stage trial of Rova-T as second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee.

Abbie said it will monitor a remaining $1 billion of intangible assets for further impairment. It added that it will continue to evaluate other Stemcentrx-related clinical development programs.

Read Also: Lupin and AbbVie announces the partnership to develop, commercialize Novel Oncology Drug

The following two tabs change content below.
MD Team

MD Team

At Medical Dialogues, we are a team of young professionals strongly advocating of the transparency in the medical sector through the free flow of medical information, health and medical news. MD Team covers a variety of news related to the healthcare, pharma and medical device industry in India. Our team can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751


Source: Reuters
0 comment(s) on Abbvie to record $4 billion impairment charges on Stemcentrx assets

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted